Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUBLC3)

Drug Name

ABO-101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Mucopolysaccharidosis	5C56.3	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Alpha-N-acetylglucosaminidase (NAGLU)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
N-Acetyl-D-glucosamine	DM1XBWR	Autoimmune diabetes	5A10	Approved	[2]
BMN 250	DMM25B1	Mucopolysaccharidosis type IIIB	5C56.3Y	Phase 1/2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-N-acetylglucosaminidase (NAGLU)	TTDM6HZ	ANAG_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Abeona Therapeutics.
2	Development of bFGF-Chitosan Matrices and Their Interactions with Human Dermal Fibroblast Cells. J Biomater Sci Polym Ed. 2009;20(10):1335-51.
3	Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B. Drug Deliv Transl Res. 2020 Apr;10(2):425-439.